Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
EMA Recommends Suspension of 700 Drugs Tested at GVK Site GVK Biosciences argues that EMA’s recommended suspension of 700 drugs is disproportional to reported infractions.
Nelson Patterson has been elected to Pharma & Biopharma Outsourcing Association board.
There are significant differences between small molecules and biologics fill/finish capacity.
Bristol-Myers Squibb and Johnson & Johnson announced FDA-approval of Evotaz and Prezcobix, combination HIV-1 infection treatments.
FDA guidance discusses factors to consider in evaluation of photosafety and describes nonclinical photosafety tests.
The agency creates an electronic central repository to facilitate drug safety assessment reports.
Ingredients InsiderCynthia ChallenerFDA Approves Novel Treatments in 2014